Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

Area of Science:

• Medical Oncology
• Pulmonary Medicine
• Clinical Trial Research

Background:

• Stage IV non-small cell lung cancer (NSCLC) without driver alterations presents unique treatment challenges.
• Existing guidelines require continuous updates to reflect evolving therapeutic landscapes.

Purpose of the Study:

• To provide updated, evidence-based recommendations for the management of stage IV NSCLC in patients lacking driver alterations.
• To consolidate and present the latest findings from clinical research to guide treatment decisions.

Main Methods:

• An ongoing systematic review of randomized clinical trials (RCTs) forms the basis of these continually updated recommendations.
• An Expert Panel reviewed literature from February to October 2023, including meta-analyses and RCTs, focusing on efficacy and safety outcomes.

Main Results:

• The guideline incorporates all previous updates and reflects the comprehensive body of evidence reviewed.
• Ten new randomized controlled trials were identified in the most recent literature search.

Conclusions:

• Updated evidence-based recommendations are provided for first, second, and subsequent treatment options for NSCLC patients without driver alterations.
• These recommendations aim to optimize therapeutic strategies and improve outcomes for this patient population.